developed avidin-capped mesoporous silica nanoparticles (MSNs) functionalized with linkers that are specifically cleaved by matrix metalloproteinase 9 (MMP9, highly expressed in lung cancer), allowing for controlled release of chemotherapeutics from the MSNs in high MMP9-expressing tumor areas (Figure 4E). Here, MMP9 is linked to lung carcinoma.